Eight years ago, when the Kansas City Clinical Oncology Program began operation, we determined that the purpose of our Program would bc to develop and sustain cancer research and treatment programs. These programs would benefit cancer patients and their families in the region through the promotion of the highest possible quality of cancer care. A sequence of collectively determined objectives have aided KCCOP in both our past achievement and our ongoing development. Our objectives are: to maintain and expand our relationships with SWOG, RTOG and MDA, and to add NSABP as a research base to increase accrual to high priority breast cancer protocols; to establish and improve data management systems; to conduct protocol research and cancer control research through KCCOP clinical trials and to act as a resource base for future NCI initiatives; to maintain and expand our quality control program, to assure continued performance above NCI and research base standards; and to work with NCI and research bases in the development and implementation of cancer control research protocols. Several prominent characteristics distinguish the KCCOP. KCCOP has a very strong base of support from our six member hospitals, who have contributed nearly half a million dollars to the Program since its inception. We have a track record of high levels of involvement with our research bases and in the development of protocols. Our accrual levels to clinical trials are exceptional and in this past year we posted 75.1 credits. These accrual levels will remain high, due to Kansas City's substantial population and resource base. A record of quality and punctuality in data management, as shown by our SWOG review of 98% timeliness and 100% completeness, is yet another of our Program's attributes. Our Principal Investigator, Associate Principal Investigator and Investigators each have extensive experience in clinical research. The combination of each of these factors assures the National Cancer Institute that KCCOP will continue to perform well above NCI requirements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035176-09
Application #
3557572
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-15
Project End
1995-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Baptist Medical Center
Department
Type
DUNS #
City
Kansas City
State
MO
Country
United States
Zip Code
64131
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7
Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5

Showing the most recent 10 out of 147 publications